The Truth Is In…

in Stock Analysis

Who ever said, “vino veritas” (in wine, there is truth), hasn’t written enough. I say, “in writing veritas.”   MarketWatch asked me to write an article about one’s investment strategy in the interest rate environment on the horizon.  When I first sat down to write, I thought that I was a bit neutral on the direction of interest rates. However, by the time I finished (as you’ll see), it was painfully obvious that interest rates are more likely to go down than up. It’s a story of global prosperity that has been in part prepped up by finite sources (mostly debt).

I would not bet my career or even a bottle of fine beer (Fat Tire – those in Colorado will know), but there are too many “uncertainties” on the horizon for higher interest rates.  In the article, I offered two stocks, Glaxosmithkline (GSK) and Johnson & Johnson (JNJ)  that should do well in any interest rate environment.

Tags:

Leave a Reply

Latest from Stock Analysis

Uninvestable Tesla

Tesla is an uninvestable stock for me, not just because of its
Go to Top

Tired of generic investment advice?

CUT THROUGH THE BS - JOIN 30,000 READERS

"Vitaliy Katsenelson is the new Benjamin Graham."

- Forbes

DON`T MISS OUT!

GET THE LATEST INVESTMENT ARTICLES IN YOUR INBOX EVERY WEEK

"Vitaliy Katsenelson is the new Benjamin Graham."

- Forbes

JOIN OUR NEWSLETTER

Tired of generic investment advice?